alopecia/tyrosine

Linket gemmes på udklipsholderen

Vælg sorteringstype

Side 1 fra 111 resultater

A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

OBJECTIVE Nilotinib, a recently approved multitargeted tyrosine kinase inhibitor targeting the BCR-Abl translocation involved in chronic myelogenous leukemia, reportedly produces alopecia according to the package insert, but clinical and histologic descriptions of the alopecia are lacking. METHODS A

Demonstration of autoantibodies against tyrosine hydroxylase in patients with alopecia areata.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND There is strong evidence to suggest that alopecia areata (AA) is a tissue-specific, T cell-mediated autoimmune disease, which is usually characterized by patchy areas of hair loss on the scalp. Tyrosine hydroxylase (TH) is a known B-cell autoantigen in patients with autoimmune

Protein tyrosine phosphatase nonreceptor type 22 gene polymorphism in alopecia areata: Does it have an association with disease severity?

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Alopecia areata is a condition involving hair loss from certain or all areas of the body. It has been considered as an immune-mediated disease, characterized by the infiltration of CD4+ and CD8+ lymphocytes in the hair follicles.The study aimed to assess

Epitopes, avidity and IgG subclasses of tyrosine hydroxylase autoantibodies in vitiligo and alopecia areata patients.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND We previously detected antibodies against tyrosine hydroxylase (TH) in 23% of patients with nonsegmental vitiligo and in 19% of patients with alopecia areata (AA). OBJECTIVE To identify TH epitopes recognized by TH antibodies in patients with vitiligo and AA. METHODS Recombinant plasmids

Epidemiologic and genetic characteristics of alopecia areata (part 2).

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Alopecia areata (AA) is hypothesized to be an organ-specific autoimmune disease mediated by T cells to the hair follicles. Despite the fact that most cases of AA are sporadic, there is an accumulation of evidence that AA is a complex multigenetic trait with components of inherited predisposition. In

Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

OBJECTIVE This report describes the 2016 consensus of the Taiwanese Dermatological Association (TDA) regarding the definition, classification, diagnosis, prevention, and management of skin toxicities resulting from treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors

How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND Dermatological toxicities associated with tyrosine kinase inhibitors (TKIs) are commonly graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). A new tool has been proposed by the Multinational Association for Supportive Care in Cancer

A case of cicatricial alopecia associated with erlotinib.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its role in tumor cells, EGFR is also an important regulator of growth and differentiation in the skin

Successful management of imatinib despite alopecia and nail necrosis.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Imatinib mesylate selectively inhibits bcr/abl and other non-specific tyrosine kinases, such as c-kit and platelet derived growth factor (PDGF) receptor and successfully used to treat chronic myeloid leukaemia (CML). In most cases, the drug is well tolerated: however, side effects can be seen. Hair

Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

OBJECTIVE We studied the safety and tolerability of telatinib, an orally available, small-molecule tyrosine kinase inhibitor of the vascular endothelial growth factor receptor (VEGFR-2/VEGFR-3), platelet-derived growth factor receptor beta, and c-Kit in combination with capecitabine and

Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and Management.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Several tyrosine kinase inhibitors (TKIs) are now approved for the treatment of chronic myeloid leukemia in chronic phase. The efficacy of these drugs has been repeatedly demonstrated, as has their tolerability in most patients. However, late and chronic toxicities become an important issue for many

The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

Background: Von Hippel-Lindau (VHL) disease is an autosomal-dominant hereditary cancer syndrome. Currently, studies on tyrosine kinase inhibitor (TKI) therapy for VHL disease are scarce. In this study, we retrospectively evaluated the efficacy and safety of four TKIs in patients with VHL

Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND Most patients with advanced non-small-cell lung cancer (NSCLC) require systemic chemotherapy. Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors (TKI; e.g., sorafenib, sunitinib, cediranib, vandetanib, BIBF 1120, pazopanib, axitinib) has recently been evaluated in

The R620W polymorphism in PTPN22 confers general susceptibility for the development of alopecia areata.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND The functional R620W (c.1858C>T) variant of the protein tyrosine phosphatase nonreceptor 22 gene (PTPN22) has been associated with a variety of autoimmune disorders. A recent study has suggested that R620W also contributes to the severe form of alopecia areata (AA). OBJECTIVE We sought to

Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female.

Kun registrerede brugere kan oversætte artikler

Log ind / Tilmeld

BACKGROUND Sunitinib is a multiple receptor tyrosine kinase inhibitor (TKI) used for the treatment of renal cell carcinoma (RCC). It increases the median survival considerably with minimum side effects. Alopecia is one of the rare side effects. Metastasis to the ovary is also rare. We report a case

Tidligere
1
2
3
4
5
6
7
8
Næste

Deltag i vores
facebook-side

Herbal & Natural Medicine

Den mest komplette database med medicinske urter understøttet af videnskab

Arbejder på 55 sprog
Urtekurer, der understøttes af videnskab
Urtegenkendelse ved billede
Interaktivt GPS-kort - tag urter på stedet (kommer snart)
Læs videnskabelige publikationer relateret til din søgning
Søg medicinske urter efter deres virkninger
Organiser dine interesser og hold dig opdateret med nyhedsundersøgelser, kliniske forsøg og patenter

Skriv et symptom eller en sygdom, og læs om urter, der kan hjælpe, skriv en urt og se sygdomme og symptomer, den bruges mod.
* Al information er baseret på offentliggjort videnskabelig forskning